OVERVIEW OF ACTIVITY
Non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) comprise a heterogeneous group of lymphoproliferative disorders and belong to one of the most rapidly evolving fields in hematology and oncology. Published results from ongoing clinical trials lead to the continual emergence of new therapeutic agents and changes in the use of existing treatments. Individualized treatment decisions are driven by disease-specific and patient-specific characteristics. In order to offer optimal patient care — including the option of clinical trial participation — practicing medical oncologists and hematologists must be well informed of these advances. To provide clinicians with therapeutic strategies to address the disparate needs of patients with NHL or CLL, the Visiting Professors audio series employs an innovative case-based approach that unites the perspectives of leading NHL/CLL investigators and community oncologists as they explore the intricacies of making treatment decisions. Upon completion of this CME activity, medical oncologists and hematologists should be able to formulate an up-to-date and more complete approach to the care of patients with NHL or CLL.
LEARNING OBJECTIVES
- Use case-based learning, innovative communication strategies and shared clinical insight to provide comprehensive and compassionate oncology care.
- Refine current treatment approaches through appraisal of therapeutic advances in NHL and CLL.
- Communicate the existing and emerging therapeutic roles of proteasome inhibitors and IMiDs® to patients with NHL.
- Summarize the clinical results of combinations including novel alkylating agents such as bendamustine in the up-front treatment of mantle-cell lymphoma.
- Recall the rationale for and design of clinical trials investigating proteasome inhibitors as part of initial therapy in diffuse large B-cell lymphoma.
- Use prognostic and predictive clinical and molecular markers to aid in treatment decision-making for NHL and CLL.
- Counsel appropriately selected patients about the availability of ongoing clinical trial participation.
ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Research To Practice designates this educational activity for a maximum of 3
AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
HOW TO USE THIS CME ACTIVITY
This CME activity contains both audio and print components. To receive credit, the participant should listen to the audio MP3s, read the text portion and complete the Post-test and Educational Assessment and Credit Form located on our website at CME.ResearchToPractice.com. The text portion of this activity contains edited comments, clinical trial schemas, graphics and references that supplement the audio MP3s, as well as links to relevant full-text articles, abstracts, trial information and other web resources.
CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY —
Drs Morganstein and Deutsch had no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:
Dr Leonard —
Consulting Agreements: Biogen Idec, Biotest Pharmaceuticals Corporation, Calistoga Pharmaceuticals Inc, Celgene Corporation, Cephalon Inc, CT International, Eisai Inc, EMD Serono Inc, Genentech BioOncology, GlaxoSmithKline, Gloucester Pharmaceuticals, Immunomedics Inc, Intellikine, Johnson & Johnson Pharmaceuticals, Millennium Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi-Aventis, Wyeth.
Dr Cheson —
Advisory Committee: Celgene Corporation, Cephalon Inc, GlaxoSmithKline, Millennium Pharmaceuticals Inc, Pfizer Inc;
Speakers Bureau: Celgene Corporation, Cephalon Inc.
EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abraxis BioScience, Allos Therapeutics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, Genzyme Corporation, Lilly USA LLC, Millennium Pharmaceuticals Inc, Monogram BioSciences Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi-Aventis and Spectrum Pharmaceuticals Inc.
RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
This program is supported by educational grants from Celgene Corporation, Cephalon Inc, Genentech BioOncology/Biogen Idec, Genzyme Corporation and Millennium Pharmaceuticals Inc.
Hardware/Software Requirements:
An Internet connection that is at least 28.8 Kbps
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
Macromedia Flash plug-in 6.0 or greater
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio
Last review date: August 2010
Expiration date: August 2011
